The Uab Research Foundation

Becton Dickinson and Company Limited

Other

Beijing Cotimes Biotech Co. Ltd.

Beijing Sinotau Bio-pharmaceuticals Technology Co., Ltd.

Tong Zhou

Robert P Kimberly

William J Koopman

Donald J Buchsbaum

Kimihisa Ichikawa

Albert F LoBuglio

Timothy Roy Hansen

Jun Ohsumi

John D Mountz

Dwight Livingston

Mark A Talmer

Kevin Bailey

Gerard J Sevigny

Donald E Gorelick

Takeshi Isoyama

Andre Scherz

Spencer Lovette

Christopher M Embres

Jianhua Cheng

Albert F Lobuglio

Kenneth L Rinehart

John D Mantlo

Zhe Li

Enyun Shen

Carl Edwards, Iii

Huang-Ge Zhang

Xian Chen

Kimberly Foreman

Kimishisa Ichikawa

Richard Scott Jope

Changdan Liu

Fengqi Cao

Xiuli Jin

Jun Oshumi

Provided is an isolated antibody or antigen-binding fragment thereof that binds specifically to human CD-L1 protein, a nucleic acid molecule encoding the same, therapeutic compositions thereof, and their use to treat a PD-L1 related disease, such as a tumor which is PD-L1 positive.

Anti-PD-L1 antibody and use thereof

Systems and methods for positive dispense verification. In one aspect, a system has a plurality of light emitters. The light from the emitters is directed toward a plurality of light detectors across a proximately horizontal plane. The liquid dispense device is positioned above the horizontal plane of light emission from the plurality of light emitters to the plurality of light detectors such that the dispensed liquid will travel through the horizontal plane defined by the emitted light and onto the container being inoculated. Each of the plurality of detectors is coupled to an amplifier. The amplifier generates a signal in response to an interrupt in the transmission of light from the light emitters to the light detectors when the light path is disrupted by the dispense of liquid confirming the liquid was dispensed onto the container.

Positive dispense verification sensor

The present disclosure describes pipette tips having an absorbent material (e.g., a flocking material) anchored to a distal end of the pipette tip and related methods of use. In some embodiments, the flocked pipette tips can be used in an automated process and/or system, wherein the contact between the pipette tips and either a sample or a culture medium can be automatically sensed for accurate sample collection and/or dispense. In some embodiments, automatic detection of the liquid interface may be accomplished by detecting a threshold change in capacitance when the pipette tip contacts the sample liquid interface (e.g., for sample collection) or the agar interface (e.g., for sample release). In some embodiments, the automated process and/or system may utilize one or more predetermined, fixed heights for collecting samples and/or depositing samples.

Unique sample transfer device for an automated pipettor for processing a variety of clinical microbiological specimens

Provided herein are methods of treating a subject with cancer comprising administering to the subject a death receptor agonist. Also provided herein are methods of screening a breast cancer cell for responsiveness to a DR5 agonist. Further provided herein are antibodies that selectively bind an N-terminal CARD of DDX3, a DDX3 lacking an N-terminal CARD, and an 80 kDa baculovirus TAP repeat (BIR).

Treating basal-like genotype cancers

A system for automatically processing a biological specimen is provided that includes an elevator comprising a plurality of shelves configured to receive a plurality of sample trays. The trays may comprise a plurality of sample containers containing a sample and having a plurality of respective caps engaged therewith. The trays may further include a plurality of centrifuge tube racks each containing a plurality of centrifuge tubes. The system may include a first transport mechanism, a second transport mechanism and a third transport mechanism. The system may include a chain-of-custody device configured to read identifiers on each of the containers. The system may also include a pipetting device configured to remove a portion from the sample containers and dispense the sample into the centrifuge tubes.

System and method for automated sample preparation

An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.

Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject.

HER3 antibodies and uses thereof

Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.

Agents and methods related to screening for resistance to DR5 and reducing resistance to DR5 agonists

Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 and uses thereof

Provided is a method of determining the level of resistance or sensitivity of cancer stem cells to a death receptor agonist. The method includes detecting the level of IAP in one or more DR5/DDX3/IAP complexes in or from the cancer stem cells. Also provided is a method of killing cancer stem cells in a subject and a method of reducing the risk of cancer recurrence in a subject.

Targeting cancer stem cells with DR5 agonists

Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists

Growing community of inventors

Birmingham, AL, United States of America

Tong Zhou